Exhibit 10.15


 


First
Amendment to lbs-008 research and development 

services agreement


 


This
First Amendment to LBS-008 Research and Development Services Agreement (this “Amendment”), effective as of Feb
23, 2022 (“Effective Date”), is entered into by and between Belite Bio, Inc, a Cayman corporation, with
contact office located at 5820 Oberlin Drive, Suite 101, San Diego CA, 92121 USA (“Belite Inc”) and Lin BioScience, Inc.,
a Taiwan corporation, located at 12F., No.68, Sec. 5, Zhongxiao E. Rd., Xinyi Dist., Taipei City 110, Taiwan (“Lin Inc.”).


 


BACKGROUND


 


	A.	The Parties entered into that
                                            certain LBS-008 Research and Development Services Agreement, dated July 1st, 2021 (the
                                            “Agreement”), whereby Belite Inc and Lin Inc. set forth their agreements
                                            with respect to certain services to be provided by Lin Inc.



 


	B.	In consideration of Taiwan’s
                                            laws and regulations, including but not limitation of the qualification of pharmaceutical
                                            firms of Pharmaceutical Affairs Act the Parties desire to amend the Agreement to clarify
                                            the terms specified herein.



 


NOW,
THEREFORE, in consideration of the premises and mutual promises and covenants contained herein, the Parties hereto agree
as follows:


 


		1.	Section 4 of the Agreement is hereby amended by deleting all of the current provisions of Section 4
and inserting in lieu thereof the following:



 


“Deliverables
and IPR”


 


		(a)	Deliverables. Anything discovered, invented, or developed by Lin Inc. or its personnel in the course
of the Services (“Inventions”) and all Deliverables, including but not limited to the data, certificate, or designation obtained
or received by Lin Inc. in the course of the Services, are and shall remain the sole and exclusive property of Belite Inc. Lin Inc. hereby
assigns to Belite Inc all Lin Inc.’s right, title and interest in and to any Inventions and Deliverables. Lin Inc. agrees to (1) promptly
and fully disclose any Inventions to Belite Inc, (2) assign all of Lin Inc.’s right, title and interest in and to any such
Inventions and Deliverables to Belite Inc without other consideration or royalty, except the fees and expenses as prescribed in Section 3,
and (3) execute all applications, assignments or other instruments reasonably requested by Belite Inc.



 


		(b)	IPR. Belite Inc hereby grants Lin Inc.
a revocable, non-exclusive, non-transferable, royalty-free license (with the right to grant and authorize sublicenses) under Belite Bio’s
Retinol Binding Protein 4 (“RBP4”)-related patents in Taiwan, to the extent that is necessary for Lin Inc. to
perform the Services. Lin Inc. acknowledges and agrees that Belite Inc is the sole and exclusive owner of all IPR that Lin Inc. will directly
or indirectly manage, develop or assist in the performance of the Services.



 


		2.	The Agreement, as amended herein, is ratified and confirmed.



 






    1


     


    

 


		3.	All other terms and conditions of the Agreement remain unchanged and in full force and effect.



 


		4.	This Amendment may be executed in counterparts (including by facsimile or other electronic transmission),
all of which together shall constitute an agreement binding on all the Parties, notwithstanding that all such Parties are not signatories
to the original or the same counterpart. Each Party shall become bound by this Amendment immediately upon affixing its signature hereto.



 






    2


     


    

 


IN
WITNESS WHEREOF, Belite Inc’s and Lin Inc.’s authorized representatives have duly executed this Amendment below to
indicate their assent to its terms:


 


	Belite Bio, Inc	 	Lin BioScience, Inc.
	 	 	 
	Signature:	/s/ Tom Lin	 	Signature:	/s/ Tom Lin
	Print
    Name:	Tom Lin	 	Print
    Name:	Tom Lin
	Title:	Director	 	Title:	Chairman


 






    3